Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MSM · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1g | ACTIVE_COMPARATOR | METHYLSULFONYLMETHANE |
| 3g | ACTIVE_COMPARATOR | METHYLSULFONYLMETHANE |
| 6g | ACTIVE_COMPARATOR | METHYLSULFONYLMETHANE |
| Name | Type | Description |
|---|---|---|
| MSM | DIETARY_SUPPLEMENT | - |
Inclusion Criteria: * Healthy volunteers ≥ 18 and ≤ 65 years of age * Subjects with history of nasal congestion in response to pollen, dust mites, cat dander, and/or dog dander * Subjects who score "moderate" or "severe" on the VAS Nasal Symptom Score in response to an allergenic challenge at scree...
MSM is an investigational product being studied for nasal breathing. It is currently in Phase 2 clinical development by Medicus Pharma Ltd. (MDCX). The product is being evaluated for its effects on nasal provocation with a standardized allergenic challenge.
MSM is being developed by Medicus Pharma Ltd., a company traded under the ticker MDCX. The product is currently in Phase 2 clinical development for nasal breathing.
MSM is in Phase 2 clinical development. It is an investigational product and has not been approved by regulatory authorities. A Phase 2 clinical trial for MSM has been completed.
MSM has one completed Phase 2 clinical trial, identified as NCT02342483. The trial, titled 'MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge,' enrolled 15 participants and studied the product for nasal breathing.
Yes, MSM is being studied in a randomized, double-blind, active-controlled clinical trial. The completed Phase 2 trial (NCT02342483) enrolled 15 participants and included healthy volunteers aged 18 years and older.